NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05027633 2026-03-20
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT05553808 2023-01-19
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
GlaxoSmithKline
Phase 2 Completed
NCT01869192 2019-09-24
Phase II Trial for Large ER-Negative Breast Cancers
University of Colorado, Denver
Phase 2 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT00226239 2017-07-11
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT01472029 2017-06-19
HerFLOT
AIO-Studien-gGmbH
Phase 2 Completed
NCT00177255 2016-02-08
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
University of Pittsburgh
Phase 2 Terminated
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00432315 2010-09-14
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed